NEW YORK, March 30 (Reuters) - Prostate cancer vaccine Provenge has long incited passions unlike any other cancer therapy. Doctors who raised doubts about it received death threats. Health regulators ...

November 18, 2010 — The prostate cancer vaccine sipuleucel-T (Provenge, Dendreon) received a middling vote of confidence for its on-label use and what amounted to a thumbs-down vote for its off-label ...

Dendreon filed for bankruptcy protection on Monday after sales of Provenge fell way short of expectations and the company could not pay off a huge debt coming due. By Andrew Pollack Costly treatments ...

WASHINGTON - Medicare officials confirmed Thursday that the program will cover the $93,000 price tag for prostate-cancer drug Provenge, an innovative therapy that typically gives men suffering from an ...

WASHINGTON - A first-of-a-kind prostate cancer treatment that uses the body's immune system to fight the disease received federal approval Thursday, offering an important alternative to more taxing ...